FDA Approves F8 Formulation of Theratechnologies' Tesamorelin for HIV-Associated Lipodystrophy
Автор: Contagion_Live
Загружено: 2025-04-04
Просмотров: 212
The FDA has approved Theratechnologies’ supplemental Biologics License Application (sBLA) for EGRIFTA WR (Tesamorelin F8), a treatment for excess visceral abdominal fat in adults with HIV-associated lipodystrophy. This new formulation replaces EGRIFTA SV, reducing patient burden and improving treatment adherence by offering weekly reconstitution instead of daily.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке: